Company intelligence / Profile preview

Boundless AI

San Diego, California, United Statesgetboundless.ai ↗

Ownership: Private
Development stage: Commercial

Overview

Boundless Bio is a clinical-stage precision oncology company developing therapies targeting extrachromosomal DNA (ecDNA) in oncogene-amplified cancers. Its lead program BBI‑355 targets Chk1 and has entered Phase 1 trials. BBI‑825, targeting ribonucleotide reductase, is also in Phase 1. A novel kinesin degrader program has selected its development candidate BBI‑940 with IND submission planned for the first half of 2026. The company recently prioritized its portfolio to focus on combination therapy approaches and extended its cash runway into the first half of 2028.

Therapeutic areas: Oncology
Modalities: Small moleculeGene therapyChemical drug
Industry: Biotech

Partnerships

BayerArch Venture Partners

Beyond the preview

Go deeper on Boundless AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Boundless AI.

Explore the full profile